Analyst Activity – Stifel Nicolaus Reiterates Buy on Akcea Therapeutics (NASDAQ:AKCA)

Analyst Ratings For Akcea Therapeutics (NASDAQ:AKCA)

Story continues below

Today, Stifel Nicolaus reiterated its Buy rating on Akcea Therapeutics (NASDAQ:AKCA) with a price target of $30.00.

Some recent analyst ratings include

  • 3/16/2018-Stifel Nicolaus Reiterated Rating of Buy .
  • 3/15/2018-Wells Fargo & Co Upgrade from a “Market Perform ” rating to a ” Outperform” rating.
  • 2/27/2018-Cowen was Downgraded by analysts at Cowen from a “Outperform ” rating to a ” Market Perform” rating.


  • On 7/19/2017 Ionis Pharmaceuticals Inc, Major Shareholder, bought 3,125,000 with an average share price of $8.00 per share and the total transaction amounting to $25,000,000.00.

Recent Trading Activity for Akcea Therapeutics (NASDAQ:AKCA)
Shares of Akcea Therapeutics closed the previous trading session at with 193503 shares trading hands.

An ad to help with our costs